Skip to main content

Table 1 Table of assessments

From: Exemplar Hospital Initiation Trial to Enhance Treatment Engagement (EXHIT ENTRE): protocol for CTN-0098 an open-label randomized comparative effectiveness trial of extended-release buprenorphine versus treatment as usual on post-hospital treatment engagement for hospitalized patients with opioid use disorder

 

Prescreening

Screening/

Baselinea

Randomization

TAU/XR-BUP Initiation

Date of Discharge

Follow-Up

As Needed

DAY

    

0

34

90

180

 

General measures

Prescreen Approach Log

X

        

Verbal Consent

X

        

Prescreening Form

X

        

Written Informed Consent and Quiz

 

X

       

Inclusion/Exclusion

 

X

       

Locator Form

 

X

   

X

X

  

PhenX [30] Core Tier 1 Forms

 

X

       

Demographics Forms

 

X

       

Treatment Satisfaction Survey

       

X

 

Treatment Initiation and Non-Initiation

   

X

     

Hospitalization MOUD

    

X

    

Marijuana Use Assessment

 

X

       

COVID-19 Impact Assessment

 

X

   

X

X

X

 

Timeline Followback (TLFB) (Medications)

     

X

X

X

 

Study Completion Form

       

X

 

Measure of Primary and Secondary Outcomes

Engagement in MOUD Post Hospital Discharge

     

X

X

X

 

Hospitalization and ED Utilization (Related or Not to OUD)

     

X

X

X

 

Urine Drug Screen

 

X

   

X

X

X

 

Timeline Followback (TLFB) (Drug/Alcohol) [31, 32]

 

X

   

X

X

X

 

Clinical and safety assessments

Medical and Psychiatric History

 

X

       

Physical Examination

 

X

       

Injection Site Examinationb

   

X

 

X

   

Injection Site Reaction Formc

   

X

 

X

  

X

Hospitalization Diagnoses

    

X

    

Medical Comorbidity [33]

    

X

    

Vital Signs

 

X

       

DSM-5 Checklist [35]

 

X

       

Mental Health Follow-Up Assessment

        

X

Adverse Events, Including Serious Adverse Events

  

Xd

X

X

X

X

Xe

 

Prior and Concomitant Medications

 

X

X

X

X

    

Clinical Opioid Withdrawal Scaleb; f [34]

   

X

     

Clinical laboratory assessments

Pregnancy and Birth Control Assessmentg

 

X

       

Confirmed Pregnancy and Outcome

        

X

Liver Transaminases (AST and ALT)h

 

X

       

Hepatitis B, Hepatitis C, HIV Antibodyh

 

X

X

      

Genetic Samplingh

 

X

X

  

X

X

X

 

Family Origin

 

X

       

Exploratory measures

Healthcare and Services Utilization [36]

     

X

X

X

 

Pain Assessment [37]

 

X

   

X

X

X

 

Depression (PHQ-9) [38]

 

X

   

X

X

X

 

Post-Traumatic Stress Disorder (PC-PTSD-5) [39]

 

X

   

X

X

X

 

Quality of Life (WHOQOL-BREF) [40]

 

X

     

X

 

Non-Fatal Opioid Overdose

 

X

   

X

X

X

 

Fatal Opioid Overdose (collected on SAE form)

  

Xd

X

X

X

X

X

 

Addiction Severity Index-Lite (ASI-Lite) Drug and Alcohol Use [41]

 

X

     

X

 

Post-Hospitalization Medical Appointment Follow-Up

     

X

X

  

Antibiotic Adherence for OUD-Related Infectionsi

     

X

X

  

Hospital Length of Stay

    

X

X

X

X

 

Subsequent XR-BUP Injections (XR-BUP group only)

     

X

X

X

 

Receipt of Other MOUD

     

X

X

X

 

Administrative forms

Protocol Deviations

        

X

Missed Visit and Visit Documentation Form

 

X

 

X

 

X

X

X

 
  1. Notes: aCan be completed at different time points; bFor XR-BUP only; cCompleted only if reaction noted upon injection site examination; dAEs/SAEs collected only after the participant is randomized; eAt 180-days, only SAEs are collected; fCOWS is assessed twice (before and two-hours after XR-BUP initiation) for each participant randomized to XR-BUP group only; gCompleted a second time before treatment initiation if there are more than 7 days between screening/baseline and treatment initiation; hCollected only once during these visits and not at each indicated time point; iCompleted only by participants discharged from the hospital on antibiotics for drug-related skin and soft-tissue infections